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ABSTRACT
The complexity of the IGF-1 signalling axis is clearly a roadblock in targeting 
this receptor in cancer therapy. Here, we sought to identify mediators of resistance, 
and potential co-targets for IGF-1R inhibition. By using an siRNA functional screen 
with the IGF-1R tyrosine kinase inhibitor (TKI) BMS-754807 in MCF-7 cells we 
identified several genes encoding components of the DNA damage response (DDR) 
pathways as mediators of resistance to IGF-1R kinase inhibition. These included ATM 
and Ataxia Telangiectasia and RAD3-related kinase (ATR). We also observed a clear 
induction of DDR in cells that were exposed to IGF-1R TKIs (BMS-754807 and OSI-
906) as indicated by accumulation of γ-H2AX, and phosphorylated Chk1. Combination 
of the IGF-1R/IR TKIs with an ATR kinase inhibitor VE-821 resulted in additive to 
synergistic cytotoxicity compared to either drug alone. In MCF-7 cells with stably 
acquired resistance to the IGF-1R TKI (MCF-7-R), DNA damage was also observed, and 
again, dual inhibition of the ATR kinase and IGF-1R/IR kinase resulted in synergistic 
cytotoxicity. Interestingly, dual inhibition of ATR and IGF-1R was more effective in 
MCF-7-R cells than parental cells. IGF-1R TKIs also potentiated the effects of cisplatin 
in a panel of breast cancer cell lines. Overall, our findings identify induction of DDR by 
IGF-1R kinase inhibition as a rationale for co-targeting the IGF-1R with ATR kinase 
inhibitors or cisplatin, particularly in cells with acquired resistance to TKIs.
INTRODUCTION
The Insulin/Insulin-like growth factor-1 receptor 
(IR/IGF-1R) system is widely expressed, and while 
Insulin signalling is central to glucose metabolism, IGF-
1 signalling has an essential role in regulating multiple 
cellular pathways that govern cell fate, cell proliferation, 
growth, and cancer progression [1–3]. The canonical 
IGF signalling pathway recruited by the IRS scaffolding 
proteins activates PI3-Kinase, Akt, and Ras, all of which 
are potent oncogenes that are deregulated in many 
cancers [4, 5]. The IGF-1R can also be recruited to sites 
of focal adhesions to activate the FAK and MAP kinase 
pathways and promote cell motility and invasiveness 
[6–11]. Such dynamic cooperative signalling between 
IGF-1R and Integrins may contribute to invasiveness and 
metastasis of cancer cells (reviewed in [12]). IGF-1R and 
Integrin cooperation has also been linked to epithelial-to-
mesenchymal transition (EMT), a key step in metastasis 
[13] and to resistance to targeted therapies [14].
Several IGF-1R/IR inhibitors have been tested in 
clinical trials, but these inhibitors have shown limited 
efficacy [15, 16]. Despite these poor results, individual 
responses of patients within these trials were often 
striking. Figitumumab treatment led to a complete 
resolution of pulmonary metastasis [17] and Ganitumab 
treatment led to a 28 month sustained durable complete 
response in a Ewing’s sarcoma patient [18]. However, 
many other Phase II/III clinical trials, in particular 
breast, lung and pancreatic cancers, have failed to show 
clinical benefit in unselected patients. This is likely due 
to the complexity of the IR/IGF-1R signalling axis, 
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compensatory mechanisms through other receptors, 
and a lack of predictive tumour- and patient-selective 
biomarkers of response [15, 16, 19]. Much effort is now 
focused on understanding the cellular effects of IGF-1R 
inhibition, the mechanisms of resistance and sensitivity, 
the identification of reliable predictive biomarkers of 
response, and testing options for combination with other 
therapies [20]. Resistance to IGF-1R inhibition can be 
mediated by compensatory up-regulation of the IR [21, 
22] or Her2 Receptors [23] signalling pathways activated 
by MEK [24]; or mTOR activity. Compensatory signalling 
through IGF-1R can also mediate resistance to EGFR TK 
inhibitors [25]. However, effective combination therapy of 
IGF-1R inhibitors with chemotherapy or TK inhibitors has 
not yet been demonstrated.
The possibility of combining IGF-1R inhibition with 
induction of DNA damage by radiotherapy or cisplatin-
based compounds is also being explored. Double or single-
stranded breaks in DNA normally activate DNA damage 
repair mechanisms in order to maintain genome stability. 
These involve activation of the ataxia telangiectasia 
mutated (ATM) and ataxia telangiectasia and Rad3-related 
(ATR) kinases, which lead to cell cycle arrest and DNA 
repair. Suppression of IGF-1R signalling has been shown 
to enhance radiosensitivity and impair activation of ATM 
[26], and to sensitize ovarian and colon cancer cells to 
cisplatin [27, 28]. IGF-1R inhibition also enhances radio-
sensitivity in prostate cell lines due to impaired double-
stranded DNA repair mechanisms [29]. Inhibition of ATR 
has also been suggested as an attractive approach for 
sensitization of tumour cells to DNA damaging agents. 
However the impact of dual inhibition of ATR with RTKs 
such as the IGF-1R has not yet been investigated.
The aim of this study was to identify mediators of 
sensitivity or resistance to IGF-1R kinase inhibition. Using 
a targeted RNAi screen we identified a number of genes 
that sensitize cells to IGF-1R inhibition. Among these the 
DNA damage and repair genes were strongly represented 
suggesting they may be suitable targets for co-inhibition 
with IGF-1R inhibition.
RESULTS
SiRNA screen identifies potential biomarkers 
and targets for IGF-1R inhibition
To identify potential mediators of sensitivity or 
resistance to IGF-1R inhibition, we carried out a functional 
screen with a customised siRNA library that was selected 
to target 178 oncogenes or tumour suppressors (Figure 1). 
BMS-754807 is a reversible ATP competitive dual IGF-
1R/IR inhibitor, with an IC50 ranging 100nM to 25μM 
in breast cancer cell lines [30] and a recommended dose 
of 100mg daily in patients [31]. MCF-7 cells were first 
incubated with increasing concentrations of the IGF-1R/IR 
kinase inhibitor BMS-754807 in colony formation assays 
in order to determine a sub-lethal dose of inhibitor in these 
cells, which was established at 30nM (Figure 1A). BMS-
754807 was found to inhibit phosphorylation of the IGF-
1R, and activation of the PI3-K and MAPK pathways in 
response to IGF-1 (Supplementary Figure S1). Following 
transfection with the siRNA library in 96 well plates, cells 
were cultured for 24 hours and then incubated with vehicle 
or BMS-754807 (30nM) for a further 48 hrs before cell 
viability was assessed. The results were median-centred, 
log transformed and normalized to scrambled siRNA. 
Hits that affected cell viability with robust Z-scores of 
at least +/- 1 mean absolute deviation (MAD) from the 
scrambled siRNA were selected and carried forward for 
pathway analysis, while hits with at least +/- 3MAD 
were carried forward for validation studies (Figure 1B). 
Pathway analysis of the hits using DAVID functional 
annotation tool (http://david.abcc.ncifcrf.gov/content.
jsp?file=citation.html) indicated that inhibition of cell 
cycle arrest and DNA damage and repair pathways 
conferred sensitivity and in some cases resistance to 
IGF-1R inhibition (Table 1). Included in these hits was 
ATR (a key protein involved in DNA damage sensing 
and response) that when suppressed robustly sensitized 
MCF-7 cells to BMS-754807 cytotoxicity. The effects of 
suppressing ATR with siRNA were further tested in the 
ZR-75-1 ductal breast carcinoma cell line, which was 
previously shown to be resistant to IGF-1R inhibition 
(IC50 2μM for BMS-754807) [32]. Using two siRNAs 
to suppress ATR expression in these cells we observed 
that ATR knockdown significantly reduced colony 
formation in the presence of BMS-754807 (Figure 1C). 
Exposure of control cells to1μM of BMS-754807 reduced 
colony formation to 75% of the untreated control, while 
suppression of ATR produced a greater reduction in colony 
formation (65% and 45%); indicating ATR contributes to 
resistance to IGF-1R inhibition. These results confirm the 
effects observed in the siRNA screen and overall indicate 
that the DNA damage and repair response is engaged in 
responses to IGF-1R inhibition.
IGF-1R inhibition induces DNA damage and 
γ-H2AX accumulation
We were next interested to investigate the effects 
of IGF-1R inhibition on the DNA damage response in 
breast cancer cells. IGF-1R has previously been shown to 
protect cells from DNA damaging agents [33, 34], and to 
be critical for DNA repair by homologous recombination 
following radiation in prostate cancer cells [29]. We first 
observed that BMS-754807 caused a significant increase 
in DNA damage along with activation of the ATR pathway, 
as measured by the formation of γ-Histone2AX (γH2AX) 
and phosphorylation of Chk1 on Serine 345 respectively 
(Figure 2A). BMS-754807-induced DNA damage was 
further verified by immunofluorescence labelling of 
distinct γH2AX-containing foci that were visible in 
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Figure 1: Tumour suppressor and oncogene siRNA screen to identify potential biomarkers and targets for IGF-1R 
inhibition. A. Survival curve for MCF-7 cells incubated with 30nM BMS-754807 for determination of IC30. Cells were seeded into 
colony formation assays and allowed to grow for 14 days. Values are expressed as colony intensity as a percentage of the untreated control. 
B. Distribution of Z-Scores generated from the tumour suppressor and oncogene siRNA screen. Positive scores indicate potential mediators 
of sensitivity to BMS-754807, while negative scores indicate potential mediators of resistance to the drug. Red points show Z-scores for 
ATR. Graph is representative of two independent screens, and those Z-Scores which were robust across both screens were carried forward 
as potential targets. C. Survival graph showing knockdown of ATR sensitizes ZR-75-1 cells to BMS-754807. Values are expressed as 
colony intensity as a percentage of the untreated control. Exposure of control cells to 1μM of BMS-754807 reduced colony formation to 
75% of the untreated control. Suppression of ATR with two independent siRNA oligonucleotides produced a greater reduction in colony 
formation (65% and 45%); n = 3 *P<0.05, ns=not significant, Student-T-Test. Suppression of ATR was confirmed by Western blot analysis.
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the nuclei of MCF-7 cells exposed to BMS-754807 
(Supplementary Figure S2). This induction of γH2AX in 
MCF-7 cells is consistent with γH2AX induction by IGF-
1R inhibition and IGF-1R depletion observed in prostate 
cancer cells [35]. Higher concentrations of BMS-754807 
also induced DNA damage (Figure 2B) leading to a four-
fold increase in γH2AX levels. Induction of γH2AX was 
significantly reduced upon siRNA-mediated suppression 
of IGF-1R expression (Supplementary Figure S3) and 
stable suppression of IGF-1R using shRNA also induced 
γH2AX (Figure 2C). Thus, inhibition or suppression of 
IGF-1R is sufficient to induce DNA damage. Moreover, 
a second TKI targeting the IGF-1R, OSI-906, which 
strongly suppresses IGF-1 signalling in MCF-7 cells 
(Supplementary Figure S4) was also shown to increase 
induction of γH2AX (Figure 2D). Inhibition of the PI3-K 
pathway, but not the MAPK pathway led to a marked 
increase in γH2AX induction (Figure 2E and 2F). It is 
therefore likely that the increase in DNA damage induced 
by inhibition of the IGF-1R is a result of decreased 
activity of the PI-3K pathway and not the MAPK pathway. 
Overall, we conclude that suppression of IGF-1R kinase 
Table 1: List of genes identified in siRNA screen that are associated with DNA damage response and confer sensitivity 
to BMS-754807
Gene Function Sensitivity/Resistance to BMS-754807
ATM DNA Damage Sensing Resistance
ATR DNA Damage Sensing Resistance
BCL2 Anti-apoptosis Sensitivity
BLM DNA Damage Checkpoint Resistance
BRCA1 DNA Damage Repair Resistance
BRCA2 DNA Damage Repair Resistance
CAV1 DNA Damage Repair Resistance
CDKN1A Cell Cycle Arrest Resistance
CDKN1B Cell Cycle Arrest Sensitivity
CDKN2B Cell Cycle Arrest Resistance
CHEK1 DNA Damage Response/Cell Cycle Arrest Resistance
CHEK2 DNA Damage Response/Cell Cycle Arrest Sensitivity
EGR1 DNA Damage Response Resistance
ERCC1 DNA Damage Repair Resistance
FANCD2 DNA Damage Repair Resistance
FANCG DNA Damage Repair Resistance
FLI1 DNA Damage Response Resistance
GADD45A DNA Damage Response/Cell Cycle Arrest Sensitivity
HIF1A DNA Damage Response Resistance
MGMT DNA Damage Repair Sensitivity
MLH1 DNA Mismatch Repair Resistance
MSH6 DNA Mismatch Repair Resistance
PTCH1 DNA Damage Protection Resistance
RAD51 DNA Damage Repair Resistance
TP53BP2 Cell Cycle Arrest Resistance
TP53I11 Cell Cycle Arrest Resistance
XRCC5 DNA Damage Repair Sensitivity
XRCC6 DNA Damage Repair Resistance
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Figure 2: IGF-1R inhibition causes DNA damage and induction of γH2AX. A. Representative western blot showing BMS-
754807 causes DNA damage and activation of ATR, as measured by the induction of γH2AX and phosphorylated Chk1. MCF-7 cells cultured 
in complete medium were exposed to 30nM BMS-754807 over a time course of 0 to 48 hours, followed by cell lysis and immunoblotting 
with anti-phospho-IGF-1R/IR, anti-IGF-1R, anti-phospho-Chk1, anti-Chk1, anti-phospho-H2AX (γH2AX) and anti-β-Actin antibodies B. 
MCF-7 cells were exposed to 500nM of BMS-754807 for 24 hours followed by cell lysis and immunoblotting with anti-phospho-IGF-1R/
IR, anti-IGF-1R, anti-phospho-H2AX (γH2AX), or anti-β-Actin antibodies. Quantification is from 3 distinct experiments *P<0.01 Student-
T-Test. C. Whole cell lysates from MCF-7 cells stably expressing pGIPZ Scramble shRNA, pGIPZ shIGF-1R-1, or pGIPZ shIGF-1R-2 
vectors were resolved by SDS-PAGE, followed by immunoblotting with anti-IGF-1R, anti-phospho-H2AX (γH2AX), and anti-β-Actin 
antibodies. D. MCF-7 cells were exposed to 1μM of OSI-906 for 24 hours followed by cell lysis and immunoblotting with anti-phospho-
IGF-1R/IR, anti-IGF-1R, anti-phospho-H2AX (γH2AX), or anti-β-Actin antibodies. E. MCF-7 cells were exposed to 10μM LY294002 
(PI3-K inhibitor) for 24 hours followed by cell lysis and immunoblotting with anti-IGF-1R, anti-phospho-AKT, anti-AKT, anti-phospho-
H2AX (γH2AX), or anti-β-Actin antibodies. F. MCF-7 cells were exposed to 20μM of PD98059 for 24 hours followed by cell lysis and 
immunoblotting with anti-IGF-1R, anti-phospho-ERK, anti-ERK, anti-phospho-H2AX (γH2AX), or anti-β-Actin antibodies.
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activity or IGF-1R expression levels is sufficient to induce 
the DNA damage and DNA repair response pathways in 
breast cancer cells.
Combination of ATR and IGF-1R inhibitor 
decreases clonogenic growth potential
Since inhibition of the IGF-1R promoted a 
pronounced accumulation of γ-H2AX (Figure 2) and 
suppression of ATR sensitised cells to IGF-1R inhibition 
(Figure 1), we next investigated whether dual inhibition 
of IGF-1R and ATR would be effective. MCF-7 cells 
were exposed to a range of concentrations of IGF-1R 
TKI, to the selective ATR inhibitor VE-821 [36] or 
to a combination of both agents. The effectiveness of 
VE-821 in preventing ATR activation was confirmed 
by pre-incubation of cells with VE-821 prior to UV 
exposure (Supplementary Figure S5). Colonies were 
then allowed to form for 10-14 days. Combining BMS-
754807 and VE-821 led to a visible reduction in colony 
formation with concentrations of 10nM BMS-754807 
and 100nM VE-821 (Figure 3A). This inhibition 
of colony growth was notable across the range of 
combinations with total loss of colony formation at a 
concentration of 100nM BMS-754807 combined with 
1000nM of VE-821 (Figure 3B). Synergy analyses with 
the CompuSyn software [37, 38] indicated that the 
Combination Index (CI) for BMS-754807 and VE-821 
was just below 1. This suggests that the relationship 
between the two drugs was additive-to-synergistic 
between concentrations of 10 to 100nM BMS, and 100 
to 1000nM VE-821 (Figure 3C).
Since the IGF-1R inhibitor OSI-906 also promoted 
accumulation of γ-H2AX, we tested dual inhibition with 
OSI-906 and VE-821 over a range of concentrations. 
OSI-906 has been tested in clinical trials using 600mg 
intermittent dosing, leading to a corresponding plasma 
concentration of 1μM [31]. This also resulted in a more 
pronounced reduction in colony formation compared 
to cultures exposed to either agent alone (Figure 3D). 
OSI-906 and VE-821 in combination consistently 
decreased colony growth over the entire range of drug 
concentrations (Figure 3E). Synergy calculations 
indicated that the relationship between the two drugs 
was additive for most concentrations, with only 50nM 
and 500nM concentrations of each drug producing a 
synergistic relationship (Figure 3F). The dual effect of 
OSI-906 and VE-821 seemed less effective than the dual 
effect of BMS-754807 and VE-821 together. This is 
consistent with the observation that higher concentrations 
of OSI-906 are required to totally inactivate the kinase 
activity of the IGF-1R compared with BMS-754807 
(Supplementary Figures S1 and S4). Overall the data 
indicates that the combined use of IGF-1R and ATR 
inhibitors together is effective in reducing colony growth 
with a relationship ranging from additive to synergistic.
MCF-7 cells resistant to BMS-754807 
accumulate γH2AX and are sensitive to dual 
kinase inhibition of IGF-1R and ATR
Noting the potential therapeutic benefit of dual 
inhibition of IGF-1R and ATR, we next investigated 
whether the DDR contributes to resistance to the IGF-
1R inhibitor BMS-754807. An MCF-7 cell line that is 
resistant to BMS-754807 was generated by exposure to 
increasing concentrations of the inhibitor over time, until 
cells were cultured in the presence of drug at a 500nM 
concentration. The IC50 of these resistant cells (designated 
MCF-7-R) was then compared to parental MCF-7 cells 
and found to be more than 7 fold higher (Figure 4A). In 
the presence of 500nM BMS-754807, parental MCF-7 
cells induced apoptotic pathways leading to an increase in 
the levels of cleaved PARP. However in the presence of a 
similar concentration of inhibitor, MCF-7-R cells did not 
show cleavage of PARP, indicating that these cells do not 
undergo apoptosis when exposed to this concentration of 
BMS-754807 (Figure 4B).
We next asked whether these resistant cells 
exhibited γH2AX induction and activation of DNA 
damage pathways. Parental MCF-7 cells were exposed to 
500nM BMS-754807 and compared to MCF-7-R cells. 
Parental MCF-7 cells demonstrated a large increase in 
γ-H2AX and phosphorylation of Chk1compared to the 
untreated controls (Figure 4C). Intriguingly, MCF-7-R 
cells cultured in the presence of BMS-754807 retained 
induction of γH2AX and phosphorylation of Chk1 
similar to that observed in parental cells exposed to the 
drug (Figure 4C). This indicates that IGF-1R inhibition 
may still activate the DNA Damage repair pathways in 
cells made resistant to IGF-1R kinase inhibition, and 
suggests that MCF-7-R cells may be sensitive to IGF-1R 
inhibition in the presence of the ATR inhibitor. To test 
this concept further we examined whether dual inhibition 
of IGF-1R and ATR could reverse some of the resistant 
phenotype seen in these cells. Dual exposure to BMS-
754807 and VE-821 led to a visible reduction in colony 
growth compared to either drug alone (Figure 4D), and 
consistently led to a decrease in colonies across a range 
of concentrations (Figure 4E). MCF-7-R cells appeared to 
be clearly more sensitive to co-inhibition of IGF-1R and 
ATR than parental cells. Drug synergy analysis indicated 
that the relationship between the two drugs was strongly 
synergistic within the ranges of 30-100nM BMS-754807 
and 300-1000nM VE-821 (Figure 4F). These results 
collectively indicate that MCF-7 cells resistant to the IGF-
1R inhibitor BMS-754807 continue to induce activation 
of the ATR pathway in response to IGF-1R inhibition, 
and given the lower CI values, are more sensitive to ATR 
inhibition than their parental counterparts. Thus, IGF-
1R kinase inhibition combined with ATR inhibition may 
have particular therapeutic benefit in cases of acquired 
resistance to IGF-1R TKIs.
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Figure 3: Dual combination of ATR and IGF-1R inhibitors results in decreased colony growth. A. Dual inhibition of ATR 
and IGF-1R using VE-821 and BMS-754807 visibly reduces colony numbers. MCF-7 cells were seeded into colony formation assays in 
complete medium containing increasing concentrations of BMS-754807, VE-821, or BMS-754807 and VE-821 together, and allowed to 
grow for 14 days. Drugs were replenished every 4 days. The Odyssey Infrared Imaging system was used to produce images of colonies. 
B. Survival curve for MCF-7 cells exposed to increasing concentrations of BMS-754807, VE-821, or BMS-754807 and VE-821 together, 
expressed as a fraction of the untreated control (Log10 scale). Statistical significance was calculated using 2way-Anova, * indicates a 
significant difference between both BMS-754807 versus BMS-754807/VE-821 combination, and VE-821 versus BMS-754807/VE-821 
combination. N=3, P<0.05 C. Calculation of Synergy affects using CompuSyn Software. Where a Combination Index (CI) <1, two drugs 
are synergistic, where CI = 1, two drugs are additive and where a CI>1 two drugs are said to antagonistic. D. MCF-7 cells were seeded into 
colony formation assays and exposed to increasing concentrations of OSI-906, VE-821, or OSI-906 and VE-821 together, and allowed to 
grow for 14 days. Drugs were replenished every 4 days. The Odyssey Infrared Imaging system was used to produce images of assays. E. 
Survival curve for MCF-7 cells in complete medium containing increasing concentrations of OSI-906, VE-821, or OSI-906 and VE-821 
together, expressed as a fraction of the untreated control (Log10 scale). Statistical significance was calculated using 2way-Anova, * indicates 
significant difference between both OSI-906 versus OSI-906/VE-821 combination, and VE-821 versus OSI-906/VE-821 combination. 
N=3, P<0.05 F. Calculation of Synergy affects using CompuSyn Software.
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Figure 4: BMS-754807 and VE-821 synergise to reduce colony formation in BMS-754807 Resistant MCF-7 cell line. 
A. Survival curve of MCF-7 parental and MCF-7 BMS-Resistant cells treated with increasing concentrations of BMS-754807. Statistical 
significance was calculated using Student-T-Test, n=3 *P<0.05. B. MCF-7 parental and MCF-7-R cells were exposed to 500nM of BMS-
754807 for 24 hours followed by cell lysis and immunoblotting with anti-Parp and anti-β-Actin antibodies. C. MCF-7 parental and MCF-
7-R cells were maintained in complete medium or medium containing 500nM of BMS-754807 for 24 hours followed by cell lysis and 
immunoblotting with anti-IGF-1R, anti-phospho-Chk1, anti-Chk1, anti-phospho-H2AX (γH2AX), or anti-β-Actin antibodies. D. Dual 
inhibition of ATR and IGF-1R visibly reduces colony numbers. MCF-7-R cells were seeded into colony formation assays and incubated 
with increasing concentrations of BMS-754807, VE-821, or BMS-754807 and VE-821 together, and allowed to grow for 14 days. Drugs 
were replenished every 4 days. Odyssey Infrared Imaging system was used to produce images of assays. E. Survival curve for MCF-7-R 
cells incubated with increasing concentrations of BMS-754807, VE-821, or BMS-754807 and VE-821 together, expressed as a fraction of 
the untreated control (Log10 scale). Statistical significance was calculated using 2way-Anova, * indicates significant difference between 
both BMS-754807 versus BMS-754807/VE-821 combination, and VE-821 versus BMS-754807/VE-821 combination. N=3, P<0.05 F. 
Calculation of Synergy effects using CompuSyn Software. Where a Combination Index (CI) <1, two drugs are synergistic, where CI = 1, 
two drugs are additive and where a CI>1 two drugs are said to antagonistic.
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IGF-1R inhibition sensitizes breast cancer cells 
to cisplatin
DNA damaging agents have a critical role in cancer 
therapy, so we next investigated the effect of combining 
IGF-1R inhibition and cisplatin in three breast cancer cell 
lines MCF-7, ZR-75-1 and MDA-MB-231 using colony 
formation assays. IGF-1R expression levels are different 
in these cell lines (Figure 5A), with MCF-7 exhibiting 
the highest IGF-1R expression followed by ZR-75-1 and 
MDA-MB-231 cells, while all 3 cell lines are responsive 
to IGF-1 stimulation as determined by phosphorylation of 
AKT and ERK (Figure 5B-5D).
MCF-7, ZR-75-1, and MDA-MB-231 cells were 
each exposed to BMS-754807 at 30nM, 120nM, or 300nM 
in the presence of cisplatin at concentrations ranging from 
0 to 1.0 μM. BMS-754807 significantly sensitized all 
cell lines to cisplatin, reducing the IC50 from 496nM to 
4nM in MCF-7 cells (Figure 5E), from 237nM to 52nM 
in ZR-75-1 cells (Figure 5F), and from 841nM to 584nM 
in the more resistant MDA-MB-231 cells (Figure 5G). A 
similar effect was observed following siRNA-mediated 
suppression of IGF-1R in MCF-7 cells, where the IC50 
decreased from 410nM to 7nM (Figure 5H). These results 
indicate that IGF-1R suppression enhances the potential of 
cisplatin therapy in phenotypically distinct breast cancer 
cell lines, and further indicates the benefit of combining 
IGF-1R inhibitors with DNA damaging agents.
Overall, these results indicate that IGF-1R inhibition 
may be effective in combination with cisplatin in breast 
cancer cells that exhibit different levels of sensitivity to 
either the TKI or cisplatin.
DISCUSSION
Many cancers have dysfunctional DNA repair 
systems, enabling bypass of cell cycle arrest and continued 
cell division with damaged DNA, which then renders these 
cells more susceptible to extreme DNA damage caused 
by chemotherapy and radiotherapy [39, 40]. Double or 
single stranded breaks in DNA normally activate DNA 
damage repair kinases, ATM and ATR to maintain genome 
stability. The ATR inhibitor VE-821 has been shown to 
significantly enhance the sensitivity of pancreatic cancer 
cells to radiation and gemcitabine [41], to enhance the 
sensitivity of ovarian cell lines to cisplatin, topotecan, and 
veliparib [42], and to radiosensitize human promyelocyte 
leukaemia cells [43]. In general it is considered that by 
inhibiting this key component of the DNA damage repair 
pathways, cancer cells are rendered more sensitive to 
agents that cause DNA damage. Previous work has shown 
that DNA damage sensed by ATM, a kinase related to 
ATR, can induce IGF-1 expression to drive pro-survival 
signals following chemotherapy or radiation [44].
Our results are, to our knowledge, the first to 
provide evidence for the potential benefit of co-targeting 
the IGF-1R and ATR, and the results of this study are 
summarized in Figure 6. We propose that inhibition of 
IGF-1R induces concurrent activation of the DNA damage 
sensor ATR, knockdown of which is sufficient to sensitize 
cells to BMS-754807. Importantly, in MCF-7 cells that 
had acquired resistance to BMS-754807, the effects of 
combining IGF-1R and ATR kinase inhibitors resulted 
in more pronounced synergistic cytotoxicity than that 
observed in sensitive cells. Interestingly, MCF-7-R cells 
exhibited stronger synergy between BMS-754807 and VE-
821 than MCF-7 parental cells indicating that cells that are 
resistant to BMS-754807 may be more sensitive to this 
drug combination. This suggests potential for therapeutic 
combination of these two agents in cancers with acquired 
resistance to TKIs in the clinical setting. It may also be 
possible that initial treatment with the combination may 
prevent the emergence of IGF-1R inhibitor resistance by 
selectively targeting ATR-activated clones.
IGF-1R inhibition has been found to delay both non-
homologous end-joining and homologous recombination 
[29]. Therefore exposure to an IGF-1R inhibitor such 
as BMS-754807 could delay DNA damage repair and 
therefore ‘prime’ cancer cells for treatment with a DNA 
damaging agent. This could make the cells more sensitive 
to inhibition of ATR. Indeed, ATR inhibition preferentially 
targets HR-deficient cancer cells [45]. Therefore therapies 
which delay HR would be beneficial in combination 
with ATR inhibitors. Indeed in prostate cancers cells, 
suppression of RAD51, the recombinase that catalyses 
the strand invasion step of HR, sensitises cells to IGF-1R 
inhibition [35].
TKIs that inhibit the IGF-1R also inhibit the 
homologous Insulin Receptor kinase, so it is possible that 
some of the effects are caused by inhibition of IR activity. 
However, our data herein and previous reports strongly 
indicate that the effects are largely driven by IGF-1R 
inhibition because suppression of IGF-1R is sufficient to 
induce DNA damage [29, 35], and to prevent induction 
of DNA damage by IGF-1R TKIs. This conclusion is 
also supported by a study investigating the mechanism of 
action of BMS-754807 where RNA profiling analysis was 
used to compare its effects with those of IGF-1R knockout 
[46]. The results indicated that although BMS-754807 
inhibits both IGF-IR and IR, many of the gene expression 
changes caused by BMS-754807 were due to IGF-IR 
inhibition alone.
Inhibition of the PI3-K pathway appears to be 
required for the effects of IGF-1R inhibitors in inducing 
DNA damage. The AKT-PI3-K pathway has been linked 
to sensitivity to IGF-1R inhibition whereby cells over-
expressing components of the IGF-1R/PI3-K signalling 
axis were more sensitive to IGF-1R inhibition [47, 48]. 
This effect may well be may be linked to induction of 
DNA damage as observed in our study. Our data therefore 
suggested that combining selective inhibitors of PI3-K 
and ATR may also have synergistic therapeutic effects. 
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Figure 5: IGF-1R inhibition sensitizes breast cancer cells to cisplatin. A. Whole cell lysates from MDA-MB-231, BT-549, 
HCC1419, MCF-7 and ZR-75-1 cell lines were isolated and immunoblotted with anti-phopho-IGF-1R/IR, anti-IGF-1R, anti-IR, or anti-
β-Actin antibodies. B. MCF-7 cells were serum-deprived for 4 hours, stimulated with IGF-1 and immunoblotted with anti-IGF-1R, anti-
phospho-AKT, anti-AKT, anti-phospho-ERK, or anti-ERK antibodies. C. ZR-75-1 cells were serum-deprived for 4 hours, stimulated with 
IGF-1 and immunoblotted with anti-IGF-1R, anti-phospho-AKT, anti-AKT, anti-phospho-ERK, or anti-ERK antibodies. D. MDA-MB-231 
cells were serum-deprived for 4 hours, stimulated with IGF-1 and immunoblotted with anti-IGF-1R, anti-phospho-AKT, anti-AKT, anti-
phospho-ERK, or anti-ERK antibodies. E. Survival curve for MCF-7 cells incubated in complete medium with or without 30nM BMS-
754807 and increasing concentrations of cisplatin. Cells were seeded into colony formation assays and allowed to grow for 14 days. Odyssey 
Infrared Imaging system was used to quantify colonies and results are expressed as a fraction of untreated controls (Log10 scale). Student-
T-Test, n=3, *p<0.05 F. Survival curve for ZR75-1 cells incubated with or without 120nM BMS-754807 and increasing concentrations of 
cisplatin. Cells were seeded into colony formation assays and allowed to grow for 14 days. Odyssey Infrared Imaging system was used to 
quantify colonies and results are expressed as a fraction of untreated controls (Log10 scale). Student-T-Test, n=3, *p<0.05 G. Survival curve 
for MDA-MB-231 cells incubated with or without 300nM BMS-754807 and increasing concentrations of cisplatin. Cells were seeded into 
colony formation assays and allowed to grow for 14 days. The Odyssey Infrared Imaging system was used to quantify colonies and results 
are expressed as a fraction of untreated controls (Log10 scale). Student-T-Test, n=3, *p<0.05 H. Survival curve for cisplatin treatment in 
MCF-7 cells following IGF-1R siRNA knockdown. Cells were transfected with IGF-1R-targeting siRNA for 24 hrs before being seeded 
into colony formation assays in the presence of increasing concentrations of cisplatin. The Odyssey Infrared Imaging system was used to 
quantify colonies and results are expressed as a fraction of untreated controls (Log10 scale). Student-T-Test, n=3, *p<0.05.
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Figure 6: Schematic model for how dual inhibition of IGF-1R and ATR leads to increased cell death. (Left) IGF-1 
binding to IGF-1R leads to phosphorylation and activation of the IGF-1R and recruitment of IRS-1 for the activation of the PI3-K pathway. 
Following activation of PI3-K, AKT becomes phosphorylated on two key residues by PDK1 and TORC2. This allows for AKT to engage in 
pro-survival signalling. When the IGF-1R-PI3-K-AKT pathway is active, cells are protected from the cytotoxic effects of chemotherapies 
and can activate DDR and anti-apoptotic pathways to prevent cell death. (Right) In the presence of IGF-1R TKIs OSI-906 or BMS-754807, 
activation of the IGF-1R and PI3-K pathway are inhibited and DNA damage is induced in the nucleus (γH2AX). In response to γH2AX, 
ATR and other components of the DDR response are activated to repair DNA. However in the presence of VE-821, ATR cannot repair the 
damaged DNA and cell death occurs.
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Interestingly, a recent study in TNBC cell lines indicates 
beneficial effects from combining an IGF-1R/IR inhibitor 
(OSI-906) with a PI3K inhibitor (GDC-0491), which 
indicates that PI3-K is activated independently of IGF-1R 
activity [49].
Either IGF-1R kinase inhibitors or siRNA-mediated 
suppression of IGF-1R expression is sufficient to sensitize 
breast cancer cells to cisplatin treatment. Interestingly 
MCF-7 cells exhibited the greatest increase in sensitivity 
to cisplatin upon inhibition of the IGF-1R. This cell 
line has the highest expression of IGF-1R among those 
tested, and has been previously shown to be sensitive to 
IGF-1R inhibition [30]. Though not a common therapy 
for all breast cancers, cisplatin is being investigated for 
use in triple negative breast cancers, in which IGF-1R 
has been shown to have high activity [30]. The IGF-1R 
pathway was observed to be up-regulated in microarray 
analysis of Ovarian Cancer tissues while also inversely 
correlating with survival [50]. Moreover, hyper-activation 
of IGF-1R has been found to be essential for cisplatin 
resistance in ovarian cancer [51]. This suggests that the 
IGF-1R may be a potential co-targeting option for other 
cancers such as ovarian cancer that are currently treated 
with cisplatin. Despite much research there are currently 
no reliable biomarkers available to predict response [19] 
to IGF-1R inhibition. IGF-1R expression levels do not 
appear to predict IGF-1R activity [52], and the differential 
expression of signalling components in cancer cells that 
modulate IGF-1R activity may contribute to sensitivity/
resistance to anti-IGF-1R therapies (reviewed in [12]). 
This modulation has been attributed to differential 
activation of PI3-K and MAPK pathway components [47, 
48, 53, 54] as well as expression of alternative RTKs and 
Integrin receptors [55–57]. It is likely that cancers that 
are reliant on IGF-1R signalling will exhibit the greatest 
benefit from co-targeting, which again highlights the lack 
of biomarkers for IGF-1R activity as a key challenge.
In summary our study provides a mechanistic 
rationale for the combination of IGF-1R or IGF pathway 
inhibitor with ATR inhibitors or other DNA damaging 
agents in breast cancer.
MATERIALS AND METHODS
Materials
Recombinant IGF-1 was from PeproTech (Rocky 
Hill, NJ). BMS-754807 was purchased from Active 
Biochem, PD98059 and LY294002 were from Merck, 
VE-821and OSI-906 were from Selleckchem. Customized 
siRNA Library was from Qiagen. Antibodies specific 
for phospho-H2AX (Rabbit, #9718), phospho-Chk1 
(Rabbit, #2348s), Phospho-AKT (Rabbit, # 4060s), AKT 
(Mouse, #2920s), phospho-ERK (Rabbit, #4941), and 
phospho-IGF1R Y1135/1136 (Rabbit #3024) were from 
Cell Signalling Technology, Danvers, MA. Anti-Chk1 
(Mouse, #sc-8408), Anti-IGF1Rβ (Rabbit, #sc-711) and 
anti-α-Tubulin (Mouse, #sc-23948) antibodies were from 
Santa Cruz Biotechnology, Santa Cruz, CA. Anti-β-Actin 
(Mouse, #A5441) antibody was from Sigma Aldrich. Anti-
ERK2 (Mouse, #4696) antibody was from Millipore.
Cell culture, IGF-1 mediated stimulation of cells 
and viability assays
MCF-7 and ZR-75-1 cells were maintained in 
DMEM or RMPI medium, respectively, supplemented 
with 10% foetal bovine serum and 10mM L-Glutamine and 
5 mg/ml penicillin/streptomycin. Unless otherwise stated, 
western blot analysis of whole cell lysates was conducted 
from cells maintained in complete media with or without 
appropriate treatments. For analysis of cell signalling in 
response to IGF-1, cells were generally cultured at seeding 
densities that allowed for an approximate 70% confluency 
after 16 hours. Adhered cells were then washed three times 
with serum-free media (DMEM with 10mM L-Glutamine) 
and maintained in serum-free media for a total of 4 hours 
followed by stimulation with 10ng/ml IGF-1 for 10 
minutes.
Cell viability was assessed using Cell Titre Glo 
(Promega, Madison, WI), which measures ATP. Cells were 
seeded into 96 well plates, and 24 hrs later were incubated 
with BMS-754807 for a further 48 hrs. Cells were then 
lysed using Cell Titre Glo reagent and analysed using a 
spectrophotometer.
Oncogene and tumour suppressor gene siRNA 
library
Three independent siRNAs for each target tumour 
suppressor or oncogene were arrayed in a 96-well 
platform. MCF-7 cells were reverse transfected with 
10nM siRNA for 24 hrs, after which cells were treated 
with 30nM BMS or vehicle control for 48 hrs. Viability 
was assessed using Cell Titre Glo as above. Results 
were median-centred; log transformed and normalized to 
scrambled siRNA controls. Hits with robust Z-scores of at 
least +/- 1MAD from the scrambled siRNA were selected 
and carried forward for pathway analysis, while hits with 
at least +/- 3MAD were carried forward for validation 
studies.
To suppress IGF-1R expression specifically, two 
individual oligos targeting the IGF-1R were obtained from 
Qiagen (cat # S100017521 and S102624552). A non-
targeting oligonucleotide, Silencer Negative siRNA Control 
#2 (AM4311) from Ambion (Cambridgeshire, UK) was used 
as a Negative Control. Transfections were performed with a 
final concentration of 20nM siRNA using RNAiMAX. For 
siRNA transfection, cells were trypsinsed and re-suspended 
in Penicillin/Streptomycin-free culture media. siRNA 
oligonucleotides were diluted to a final volume of 162.5 μl 
in OptiMem media. RNAiMAX transfection reagent (7.5 μl 
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in 155 μl of OptiMem) was added to the siRNA solutions 
and samples were incubated for 5 minutes. 300 μl of the 
siRNA/RNAiMAX complex was pipetted to 1 well of a 
6-well plate and 8.5 x 105 cells (in a final volume of 1.2ml) 
were then added. Cells were allowed to adhere overnight 
to the tissue culture plate, in the presence of the siRNA/
RNAiMAX complex. 24 hours post-transfection, the siRNA/
RNAiMAX complex was removed and cells were reseeded 
for experiments. Suppression of IGF-1R was detected by 
western blotting with anti-IGF-1R antibodies.
Stable suppression of IGF-1R
For stable suppression of the IGF-1R cells pGIPZ 
shRNA scramble vector (catalogue ID RHS 4346) along 
with pGIPZ IGFIR ShRNA-1 (RHS4430-98705133) and 
pGIPZ IGFIR shRNA-2 (RHS 4430-98485874) were 
transfected into MCF-7 cells. Briefly, MCF-7 cells were 
seeded at a density of 1.2x 106 cells/10 cm tissue culture 
dish, in Penicillin/Streptomycin-free medium. Eighteen 
hours later, cells were transfected with relevant plasmids. 
Solution A was prepared containing 10 μg DNA/10 cm 
tissue culture dish diluted in OptiMem serum-free medium 
to 400 μl in volume. Solution B was prepared containing 
Lipofectamine 2000 at 20 μl per 10 cm tissue culture dish 
diluted in OptiMem to 400 μl in volume. Both Solution A 
and B were incubated at room temperature for 5 minutes 
in the dark prior to mixing at a ratio of 1:1 and further 
incubation at room temperature for 20 minutes. The cells 
to be transfected were washed twice with OptiMem, prior 
to addition of 800μl of the DNA/Lipofectamine in a drop-
wise fashion. 2.2ml of additional OptiMem was then added 
to each plate. Following this, the transfected cells were 
incubated at 37°C overnight. Selection of stable pools was 
then immediately commenced in DMEM complete media 
containing puromycin at a concentration of 0.5μg/ml. Drug 
containing media was regularly replenished and selection 
was deemed complete when all cells in the untransfected 
control plate where dead (~6days).
Colony formation assays
Drug sensitivity was assessed using colony formation 
assays. 2x103 (MCF-7 cell) and 4x103 (MCF-7-R cells) were 
seeded into each well of a 6 well plate. 24 hrs later, cells were 
incubated with varying concentrations of drug to determine 
a concentration that was cytotoxic to approximately 50% 
of the cells. For cisplatin and BMS-754807 combinations, 
cells were treated with a concentration of drug that killed 
approximately 30% of the cells. Cells were transfected with 
siRNA for 24 hours prior to seeding in tissue culture plates 
at low density and were allowed to grow for up to 21 days, 
or until colony growth was visible in control wells. Colonies 
were fixed in 95% Ethanol for 10 minutes and stained 
with 0.05% crystal violet in 0.1% Ethanol for 30 minutes. 
Colonies present were measured by infrared scanning using 
Odyssey Scanning Equipment. IC50 values were determined 
as the concentration that results in a 50% reduction in cell 
survival. For combination treatments with cisplatin, samples 
were compared to BMS-754807 treatment alone (100%). All 
graphs and IC50 calculations were generated using GraphPad 
Prism software, and results are generally represented on 
graphs in Log scale as a fraction of the untreated controls.
Preparation of cellular extracts and 
western blotting
Cell lysates were generated using RIPA lysis 
buffer (50mM Tris pH 7.4, 150mM NaCl, 1% NP40, 
0.5% Sodium deoxycholate, 0.1% Sodium Dodecyl 
Sulfate). Immediately prior to cell lysis fresh phosphatase 
inhibitors, Sodium Orthovanadate (Na3VO4) (1mM), 
β-Glycerophosphate (βGP) (1mM), and Sodium 
Pyrophosphate (SPP) (2.5mM), and protease inhibitors 
(Halt cocktail 1/100 dilution; AEBSF, aprotinin, 
bestatin, E-64, leupeptin and pepstatin A) were added 
to lysis buffer. Following incubation on ice for 20 
minutes, nuclear and cellular debris were removed by 
centrifugation at 14000 RPM for 15 minutes at 4°C. 
Protein concentration was determined via Bradford 
Assay utilising Bradford protein quantification reagent 
at a wavelength of 595nm (Spectramax 384). Following 
estimation of protein concentration, samples were 
denatured by boiling for 5 minutes in 5X loading buffer 
(2% w/v SDS, 8% v/v glycerol, 60mM Tris-HCL, pH6.8, 
1.2% β-mercaptoethanol, and 0.2-0.4% Bromophenol 
Blue) and equal amounts of protein were resolved by 
SDS-PAGE and analysed by western immunoblotting. 
Nitrocellulose membranes were then blocked for 1 hour 
at room temperature in Tris-buffered saline containing 
0.05% Tween 20 (TBS-T) and 5% Bovine Serum Albumin 
(w/v). All primary antibody incubations were performed 
overnight at 4°C, and secondary antibody incubations 
were for 1 hour at room temperature. Alexa Fluor 680- 
and 800-coupled anti-rabbit and anti-mouse secondary 
antibodies (LI-COR Biosciences Cambridge, UK) were 
used for detection with the Odyssey infrared imaging 
system (LI-COR Biosciences, Cambridge, UK).
Generation of BMS-754807 resistant MCF-7 cells
Parental MCF-7 cells were exposed to increasing 
step-wise increments of BMS-754807 until cells were 
proliferating successfully in the presence of each 
increased drug concentration, and a resistant pool 
had been generated. Cells were then permanently 
maintained in cell culture medium containing 500nM 
BMS-754807.
Statistical and drug relationship analysis
P values were calculated using Student-T-Test, 
or where specified using 2way-ANOVA (P<0.05). 
Quantification of drug synergism and antagonism were 
conducted using CompuSyn Software.
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